• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
SuperGen, Inc. - Product Pipeline Review - Q4 2010 Product Image

SuperGen, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 64 pages
  • GlobalData

SuperGen, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “SuperGen, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- SuperGen, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of SuperGen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the READ MORE >



List of Tables
List of Figures
SuperGen, Inc. Snapshot
SuperGen, Inc. Overview
Key Information
Key Facts
SuperGen, Inc. – Research and Development Overview
Key Therapeutic Areas
SuperGen, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
SuperGen, Inc. – Pipeline Products Glance
SuperGen, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
SuperGen, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
SuperGen, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
SuperGen, Inc. – Drug Profiles
Nipent
Product Description
Mechanism of Action
R&D Progress
Nipent
Product Description
Mechanism of Action
R&D Progress
Amuvatinib + Carboplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
Amuvatinib + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Amuvatinib + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Amuvatinib + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Amuvatinib + Topotecan
Product Description
Mechanism of Action
R&D Progress
MP-470
Product Description
Mechanism of Action
R&D Progress
Partaject Busulfan
Product Description
Mechanism of Action
R&D Progress
ETK-Inhibitor
Product Description
Mechanism of Action
R&D Progress
SGI-110
Product Description
Mechanism of Action
R&D Progress
SGI-1252
Product Description
Mechanism of Action
R&D Progress
SuperGen, Inc. – Pipeline Analysis
SuperGen, Inc. – Pipeline Products by Therapeutic Class
SuperGen, Inc. Pipeline Products By Target
SuperGen, Inc. – Pipeline Products by Molecule Type
SuperGen, Inc. – Recent Pipeline Updates
SuperGen, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Orathecin
SGI-1776
SuperGen, Inc. – Company Statement
SuperGen, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 10, 2010: SuperGen Discontinues Clinical Development Of SGI-1776
Nov 10, 2010: SuperGen Discontinues Clinical Development Of SGI-1776
Aug 03, 2009: SuperGen's MP-470 Demonstrates Clinical Benefit In Small Cell Lung Cancer And Neuroendocrine Tumor Patients
Aug 03, 2009: SuperGen's MP-470 Demonstrates Clinical Benefit In Small Cell Lung Cancer And Neuroendocrine Tumor Patients
Dec 09, 2008: SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective In Pre-Clinical Models Of Acute Lymphoblastic Leukemia
Dec 08, 2008: SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective In Pre-Clinical Models Of Acute Lymphoblastic Leukemia
Dec 02, 2008: SuperGen To Present Data At The 50th ASH Annual Meeting & Exposition For SGI-110
Nov 20, 2008: SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Nov 20, 2008: SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Nov 20, 2008: SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Financial Deals Landscape
SuperGen, Inc., Deals Volume Summary, 2004 to YTD 2010
SuperGen, Inc., Deals Summary By Region, 2004 to YTD 2010
SuperGen, Inc., Deals Summary, 2004 to YTD 2010
SuperGen, Inc. Detailed Deal Summary
Asset Purchase
Intas Pharmaceuticals Acquires Generic Etoposide From SuperGen
Acquisition
Supergen Acquires Montigen Pharmaceuticals
Equity Offering
SuperGen Completes Private Placement Of $34.3 Million
Supergen Enters Into Co-Development Agreement With GlaxoSmithKline
Licensing Agreements
SuperGen Enters Into Licensing Agreement With Targa Therapeutics
SuperGen Enters Into Licensing Agreement With MGI PHARMA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS